The selective activation of the IL-6/STAT3 axis in specific areas of the GBM/BBB interface, particularly those rich in cancer stem cells and characterized by low disruption of BBB, may represent an innovative approach to enhance drug delivery, enlarge the spectrum of chemotherapeutic drugs used and achieve the pharmacological eradication of GBM. Here, STAT3 is linked to glioblastoma.